Cadila Healthcare

Cadila Healthcare or Zydus Cadila ? an India based pharmaceutical company having presence around the world.

Cadila Healthcare Ltd., under the aegis of the Zydus Group is set up in the year 1995 and have international
presence in countries as -

 Zydus Healthcare (USA) LLC, our subsidiary in the US.

 Zydus Pharmaceuticals USA. Inc supplies finished dosage formulations to the US generic market.
 Zydus France SAS France. With product basket of 90 generic registrations.
 Zydus Healthcare Brasil Limitada , subsidiary in Brazil set up to market formulations.

The Cadila Healthcare group exports branded formulations to 43 countries around the worldwide. For growth in
exports, Zydus Cadila has been focusing on introducing new molecules. Cadila Healthcare has 560 product
registrations. Cadila Healthcare overall therapy segment is focused on cardiovasculars, gastrointestinals and pain
management to drive growth in exports. The Cadila Healthcare group markets APIs to 40 countries worldwide.

Activities:

Cadila Healthcare product portfolio covers areas like formulations, Active Pharmaceutical Ingredients (API),
diagnostics, health & dietetic foods, skin care and animal health-care.

Cadila Healthcare core divisions includes -

 Zydus Cadila.
 Zydus Alidac.
 Zydus Medica.
 Zydus Biogen.
 Zydus Neurosciences.
 Zydus Vaccicare.

Cadila Healthcare products covers Therapeutic Segments like – Anti-Infective, Anti-Epileptic, Anti-Allergic, Anti-
Depressant, Gastrointestinals, Anti-Osteoporosis, Sedative, Women's Healthcare, Anti-Rheumatic, Anti-Diabetic,
Anti-Psychotic, Tranquilizers, Pain Management and Tadalafil.

Cadila Healthcare owns blockbuster brands like and its product line includes -

Oflin OD, Clodus, NeoLoridin, Ven-OD, Isbis, Bonmax, Cartup, Zyquin, Oxeptal, Zytonin, Cefinar, Zycolchin,
Dactive, Vageston, Xet, Aldren, Serlin, Mexate, Epsolin, Euglim, Olandus, Divalpro, Topiram, Cytolog, Stilnite,
Mifegest, Linid, Mosadac, Espra, Salazar, Lamidus, Zoldac and Zydalis.

Performance:

Cadila Healthcare has registered a turnover of Rs 4211 million for the year ended 31st March 2007. Cadila
Healthcare has posted Net Profit to the tune of Rs 389 million for the year ended 31st March 2007.
Organization

Cadila Healthcare is headed by Mr Pankaj R. Patel , Chairman and Managing Director . Cadila Healthcare
Corporate Headquarter is located at:

About us
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India,
headquartered at Ahmedabad, in the state of Gujarat. Over the last five decades, it has been developing
and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around
the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to
over 50 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-
infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The company focuses on
providing high quality, appropriately priced products to its customers and supports all these with
dedicated customer service. Cadila Pharmaceuticals has a multicultural, multilingual and multinational
workforce of more than four thousand employees including over two hundred people outside India in forty-
nine countries of Africa, CIS, Japan and USA.

The company has one of the best Research and Development (R&D) setups in India, manned by more
than three hundred and fifty scientists and engineers from various disciplines including biology,
pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of
engineering. The company also participates in Public-Private partnerships for developing diagnostic,
preventive and curative pharmaceutical and diagnostic products.

Cadila Pharmaceuticals is the first Indian company to get IND approval by USFDA for clinical trials to be
conducted in India. Subsequently, the company has filed four more INDs with USFDA. Of the five INDs
filed, one is for pulmonary tuberculosis; the trial is supported by Department of Biotechnology, Govt. of
India. The remaining four are for various types of cancers, e.g., Lung Cancer, Prostrate cancer, Bladder
Cancer and Melanoma. Thus all the INDs are for providing solutions to major global health care problems.
The clinical trials on Prostrate cancer, Lung cancer and Bladder cancer are supported by Department of
Science and Technology to encourage innovations.

The company has state-of-the-art manufacturing facilities conforming to the most stringent international
cGMP norms vis-à-vis WHO-GMP, WHO, Geneva (GDF site for Anti- TB), TGA Australia (PIC/S),
USFDA, UK- MHRA, MCC-South Africa, ISO 9001 and ISO 14001. Spread over hundred acres of land,
Cadila Pharmaceuticals’ manufacturing facility at Dholka is the cynosure of all eyes, well equipped with
world-class production facilities. The company’s two Active Pharmaceutical Ingredients units at
Ankleshwar manufacture a wide-range of APIs and intermediates including three USFDA certified
products. The manufacturing facility at Samba, near Jammu, started its commercial operations in August
2006. The first overseas formulation manufacturing facility of Cadila Pharmaceuticals Ltd. has
commenced its operations in Ethiopia.
A responsible corporate citizen conscious of its duty towards various sections of the society; Cadila
Pharmaceuticals nurtures young talents; runs an ultra-modern charitable hospital in a remote area with
facilities like Telemedicine in association with Apollo Ahmedabad; works closely with NGOs by way of
assistance and support for mid-day meal programmes, among other initiatives.

Milestones
A Prelude

Cadila Pharmaceuticals (CPL) Ahmedabad, India exemplifies a spirited Indian Enterprise. Its phenomenal
growth is a corporate epic, an epoch in time nurtured by fifty-two years of rich, caring heritage. With a trail
of creditable milestones, CPL today has evolved to become the undisputed leader in the Indian
Pharmaceutical sector, with the largest therapeutic groups, it's operations spanning 45 countries. CPL is
multi-locational, with it's global offices and infrastructure.

Milestones

Today, Cadila is proud of its achievements —

 State-of-the-art formulations manufacturing facility, built to the exacting specifications of USFDA,

TGA, MCA & MCC.
 One of the best R & D set-ups in the country, manned by a 150-strong scientists' pool.
 Strong Formulations Development base.
 A host of 'Biotech' products launched, including many 'Firsts in India'.
 World's First manufacturer of Immuvac- a unique Immunomodulator.
 USFDA approvals for Fluoxetine & Ethambutol manufacturing facilities.
 ISO 9002 approved Bulk Actives (APIs) manufacturing facility, offering facilities for contract
research.
 Asia's only manufacturer of 'SULFOLANE' (Tetramethylene Sulfone).
 Significant global presence.
 Leadership in Domestic Marketing and Distribution Management.
 Leader in Indian Generics Market.

Diversifications

 Hospital Disposables including Fiberglass Casting Tape for the first time in India
 Diagnostics
  Laboratory Chemicals
 Pharmaceutical Machinery Manufacturing
 Animal Health Formulations & Feed Supplements
 Agro Business : Plant Tissue Culture and Bio-fertilizers.
 Travel Business
 Strategic Business Alliances with world-leaders

Today, Cadila Pharmaceuticals is all set to create new records, scale greater heights. It has created new
world-class production and R&D facilities, focusing on research, new process innovations leading to
patents, and meeting global standards. The Company always places the common man at its core – who
should be able to access and afford our medicines anywhere in the world. For us at Cadila, this is the only
true benchmark of excellence, and the only thing that really matters.

Patents
The Formulation Development department initiates innovative processes for a number of products. The
company has filed a host of patent applications and several more are in the pipeline. Meanwhile a few
patents have already come our way:

 Lactobacillus + Antibiotic combinations (Patents granted in Eurasia, USA, UK, ARIPO, Kenya, Sri
Lanka, India).
 Topical beta blockers with improved efficacy in ophthalmology (Patent granted in India).

Marketing Divisions
Following is an introduction to different divisions under Branded Strategic Business Unit
(SBU) :

Magna
Magna is a multi-specialty division. It maps general practitioners, consulting physicians, surgeons,
cardiologists, gastroenterologists, gynaecologists, paediatricians and nephrologists. Magna's portfolio
primarily covers gastroenterology, cardiology, gynaecology and others. Magna's major brands are 'Aciloc',
'Rabeloc', 'Cadilose', 'Envas', 'Losium', 'Caditor', 'Calcirol', 'Haemup', 'LMX', 'LMX forte', Levocide, and
'Fludac'.

Maxima
Maxima is a multispecialty division. Its portfolio covers respiratory inclusive of ENT, chest (anti
tuberculosis), dentistry, anti-infectives and orthopaedic therapies. Maxima targets ENT specialists, chest
physicians, dentists, paediatricians, orthopaedicians and surgeons. Major brands of this division are
'Lorfast', 'Vasograin', 'Symbiotik', 'Mycobutol', 'P-Zide', 'Amdepin', 'Emvit Plus', 'Cuga', and 'Immuvac'.
'Immuvac' is a unique immuno-modulator that has various applications including reducing duration of
therapy for treatment of multi drug resistant tuberculosis, and multibacillary leprosy. The division also has
certain superspecialty brands like 'Halonix' for orthopaedics.

A special task force for ophthalmology 'OTF' operates as a sub-unit of this division focusing on
opthalmologists with brands like 'Scat', 'Loptame', 'Gatt', and 'Visial' among others.

Volta
Volta is a super-specialty division. Its portfolio covers cardiology, diabetology, endocrinology,
gastroenterology, nephrology, and critical care. The division adopts three therapeutic approaches, viz.,
cardiac therapy, diabetic therapy, and critical therapy. Major brands of this division are 'Nodon', 'STPase',
'Teli', 'Envas IV', 'Glyloc', 'Glista', 'Caditor', 'Humstard'.

Oncocare
Oncocare division markets products that manage and treat cancer and tumours. Oncocare is expanding
in haematology segment to emerge as a complete division providing medicines for treatment of solid
tumour and haematological malignancies. Oncocare's major brands are 'Cadigran', 'Caditrex', 'Karplat',
'Paclicad', 'Posid', 'Kinaplat', 'Cadria L', 'Docecad', 'Filcad', 'Platin' and 'Recovarin'.

Magna XL
Magna XL division's objective is to increase reach and penetration in rural market. Explora aims to make
available quality medicines at affordable prices to people living in interior towns and villages. Explora's
portfolio covers general practitioners, consulting physicians, pediatricians, and gynaecologists. Explora's
thrust brands are 'Nuflam', 'Haem up', 'Tummy Ease', 'Happytizer', 'Lactoceff', 'Anstisept', 'Hepasave',
'LMX', 'Wormin A', and 'Fleximuv'.

Generic
Generic is a wing of pharma business. The wing covers almost all therapeutic segments. Generic directly
deals with stockists primarily, and retailers and dispensing doctors secondarily through super distributors.
A major chunk of business and promotion focuses mainly on stockists. Generic has three sub divisions,
namely, 'Generic', 'Genvista' and 'Genstar'. Generic's major brands are 'Ciprodac', 'DPhesic', 'Dexasone',
'Famonext', 'Demisone', 'Campicillin', 'Oritaxim Inj.', 'Mokcan' and 'Cotrimoxazole DS'.

Vetnova
Vetnova is animal healthcare division. It is one of the earliest and most reputed concerns in animal
healthcare. At present Vetnova happens to be one of the fastest growing enterpises harnessing the
opportunities across the market. A team of more than 100 people takes a wide range of our brands
pertaining to cattle, poultry and canine into the remotest corners of India. While some of Vetnova's brands
like 'Cal D Plus DS', 'Onfeed' and 'Cal D Min' are household names, other brands like 'Nolapse' (for
prelapse) and Endotrin (Ecbolic) are innovative offerings of Vetnova. The division is on the path to growth
and intends to take its brands beyond the borders.

Champion Brands
ENVAS
Cadila Pharmaceuticals makes India's No.1 ACE inhibitor, Envas, which has been listed among the
country's top 50 Pharma Brands, across all categories.
Other CPL brands in top 300 brands of Indian Pharmaceutical Industry are Aciloc and Haem-Up.

ACILOC
A Ranitidine preparation, Aciloc is one of India's best selling brands in this category.

LMX, SYMBIOTIK, CLAX

Antibiotics with live Lactobacilli combination, LMX, SYMBIOTIK, CLAX are the first brands of its kind in
India, for which Cadila Pharmaceuticals has applied for a worldwide patent. This unique innovation has
already been granted Indian, UK and US, Eurasian & Sri Lankan patents.

RABELOC, ACILOC RD, ZASO, MIXULIN, MONTELAST AND NODON

are some of the best selling brands in their categories.

CPL is the first company in India to introduce RABEPRAZOLE and FOSINOPRIL formulations.

Manufacturing Excellence
Pursuant to its corporate philosophy of striving for continuous improvement and betterment, the Company
has re-located its manufacturing operations at the state-of-the-art plant at Dholka, located 50 km from
Ahmedabad, the commercial capital of Gujarat. Spread over 44 acres of verdant, picturesque
surroundings, amidst lush green lawns and thick foliage, the new locale is an envied pharmaceutical
installation in the Asian sub-continent.

Truly unique in every sense of the term, the Plant’s standards and facilities can match any other,
worldwide. Seven ‘zones of cleanliness’ have been defined and adhered to, as per the 1997 GMP
guidelines of the European Union. Some of the salient features of the design concepts:
  No wood or asbestos component.
 Each zone has separate AHUs (Air Handling Units), dehumidification unit and dust extraction
systems.
 Segregation of every critical processing activity in each zone, to avoid cross-contamination.
 Adherence to stringent specifications of USFDA, MCA(UK), MCC(South Africa) and
TGA(Australia).
 Respective zones, areas and even uniforms marked with specific colours of the rainbow
(‘Indradhanush’ in the vernacular), to ensure total segregation.
 Air environment conditioned in each area with respect to temperature, humidity, filtration, particle
counts, etc.
 Conformation of each processing stage with US Federal Standard 209E class of cleanliness; viz.
100, 1,000, 10,000, 100,000 with respect to room air changes, pressure, particle count, flow
direction etc.
 Duo Pass Reverse Osmosis (RO) water system, multi-stage distillation plant, self-sanitizing,
sanitary SS 31 6L loops water, water for injection with online monitoring of pH, temperature,
conductivity and TOC requirements as per USP XXIV.
 Zero-discharge Effluent Treatment Plant constructed using technology from Advent Integrated
System, USA.
 Environment-friendly VAHP chillers.
 Rigvent heat extraction devices and Natural Skylit system in raw material, packing material and
finished good stores.
 Isolated and dedicated production facilities for B-Lactum and Cephalosporin dosage forms.
The complex also houses its own full-fledged R&D center, set up at a cost of Rs. 200 million.

The Plant is equipped with modern high-speed machines and integrated packaging lines to be cost
efficient. Extensive use of non-fill devices, collators, Brevetti visual inspection machines, multi-station
tablet presses, FFS machines, high speed vial/ampoule filler/sealers are some of the examples.

The plant—with high capacities and scope for future expansion—is capable of manufacturing all dosage
forms viz. Tablets, Capsules, Liquid Orals, Dry Syrups, Aseptic Liquid and Solid preparations, Sachets
etc.

Production Capacity
Main Pharma Production Capacity

2 Shift / day basis

Tablets  :3900 million/year

Capsules :150 million/year

Liquids :6000 Kilo Litters/year

Sterile vials :84 million/year

Ampoules :84 million/year

Granules :15.6 Tones/year

2 Shift / day basis

Beta Lactum / Cephalosporin

Dry Sterile vials :48 million/year

Dry Syrup bottles :27 million/year

Capsules :630 million/year

Tablets :510 million/year

SOFT GELATIN MANUFACTURING FACILITY

Cadila Pharmaceuticals  commissioned a modern, sophisticated manufacturing facility for Soft Gelatin
Capsules at its Jammu Complex. Designed to meet the most stringent international standards, all
operations in this plant from encapsulation to packaging, are carried out under class 100,000. All systems
are validated to meet International FDA standards, and the present capacity of one million capsules per
day can be doubled with marginal investments.

OTHER MANUFACTURING LOCATIONS

 Plant Tissue Culture, Hirapur

 Casil Industries Ltd., Pharma Machinery, Speciality Chemicals
& Soft Gelatin Capsules Manufacturing Facilities at Jammu
 Active Pharmaceutical Ingredients (APIs), Ankleshwar
Quality Control
Quality embodies the spirit of the company. Quality is apparent right from the moment you step into the
premises, in the numerous facets ingrained and internalized into the company’s ethos.

The slogan “Cadila for Quality” that was deeply etched into every logo of the Company, and subsequently
into the minds of millions, is adhered to with utmost dedication as it was years ago. A special Quality
Management Division spearheads the concept of Total Quality Management, an integration of all
functions with built-in quality.

Businesses
One of India's most reputed, Research based, tech-savvy Pharmaceutical Companies, we have been
focusing on areas - Formulations both Human and Veterinary, Active Pharmaceutical Ingredients, New
Drug Discovery, Novel Drug Delivery, Analytical Research, Phytochemistry, Biotechnology, Plant Tissue
Culture, Biosynthesis, Genetic Engineering, Vaccines, Immunoglobulins - the entire gamut of a True Life
Sciences Company.

At Cadila Pharmaceuticals, Research and Development forms the core of all the initiatives in the realm of
Biotechnology, APIs, Formulations, Plant Tissue Culture, Phytochemistry, etc. This strong R&D forms the
backbone of state-of-the-art manufacturing facilities at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat;
Samba in Jammu & Kashmir; and Addis Ababa in Ethiopia.

Diversified operations encompass Hospital Disposables and Instrumentation, Diagnostics, Specialty

Chemicals, Softgel, Pharma Machinery, Travel & Leisure. A Special Economic Zone - PhaEZ Park is
being developed by a group company. Spread over 500 acres of land at village Haripura, Dhandhuka
near Ahmedabad, PhaEZ Park is one of the largest Pharmaceutical specific SEZs in India.
Research & Developement
Spread over more than 1,05,000 sq. ft. area, Cadila Pharmaceuticals’ R & D facilities, recognized by the
Department of Science & Technology, Government of India, are manned by a 150-strong scientists’ pool.

A centralized Quality Control & Analytical Research Laboratory has been set up to meet the domestic and
international quality standards. The Company has expanded operations by building further on already
existing set-up by investing in new premises, to include modern, state-of-the-art amenities.

One of the few companies in the country carrying out collaborative research, Cadila Pharmaceuticals taps
the best scientific talent in the country and has collaborations with more than 30 leading Research and
Development centers in India.

Novel Drug Delivery Systems under development :

 Sustained Release Formulations

 Pelletization Technology
 Osmotically Releasing Oral System (OROS)
 Microparticulate Drug Delivery System
 Transdermal Patches
 Chewing Gum as Drug Delivery
Vision
"Our vision is to be a leading pharmaceutical company in India and to become a significant global player
by providing high quality, affordable and innovative solutions in medicine and treatment."

Mission
"We will discover, develop and successfully market pharmaceutical products to prevent, diagnose,
alleviate and cure diseases.

We shall provide total customer satisfaction and achieve leadership in chosen markets, products and
services across the globe, through excellence in technology, based on world-class research and
development.

We are responsible to the society. We shall be good corporate citizens and will be driven by high ethical
standards in our practices."